Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: tnk who wrote (1029)	2/15/1998 4:01:00 PM
From: invest04	Respond to of 5736

tnk...LOL, but thanks for your concern.

To: tnk who wrote (1029)	2/15/1998 5:15:00 PM
From: JanyBlueEyes	Read Replies (2) \| Respond to of 5736

Bilirubin Revisited From techstocks.com - Conference Call Transcript 8/12/97 ....This disease affects over half of all babies born and nearly 100% of all premature children. Every infant born is monitored for it. It is a liver-related disease and fundamentally occurs in varying degrees within the first two weeks of a child's life when the liver is trying to work on its own independent of the mother. If the liver doesn't take over quickly enough and the disease is not caught in time and then treated by phototherapy or exchange transfusion, the results can be varying degrees of nervous system damage/or brain damage, called Kernicterus. If left untreated, it is ultimately fatal. Scientists learned a long time ago that the disease causes a yellow staining of any affected cells. If an autopsy is performed on a child who dies from kernicterus the brain cells will be stained a yellow color. The medical community also very early on observed that the disease affected the yellow color of the baby's skin. However, the only method accurate enough to monitor it was a blood test, often taken many times a day, where a laboratory spectrophotometer would measure the stained color of the blood serum to determine in mg/dl the amount of bilirubin present. Now, with Chromatics' technology, it is possible for the health care professional to decrease blood tests and monitor the disease by using a light sensor which measures the skin of the baby's body and the incremental yellow content within this skin, painlessly and non-invasively. This is a tremendous advantage as the extensive blood drawing from infants is a truly savage procedure. Many newborns, especially preemies, don't have fully formed veins, so to obtain the blood samples the doctors or nurses have to incise and squeeze the blood out which is a brutal process, leaving scars and moreover, is labor intensive, especially when this procedure occurs in a good size nursery with an average of 30 babies needing multiple tests per day. Bone up on your facts here: Message 3079705 Jane